Subcutaneous Herceptin Combo Therapy for Certain Breast Cancer Patients Granted FDA Approval
February 28th 2019Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer.
Read More